Patents by Inventor Ian Tarpey

Ian Tarpey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210177961
    Abstract: The present invention provides a vaccine for feline leukemia virus and methods of making and using the vaccine alone, or in combinations with other protective agents.
    Type: Application
    Filed: November 5, 2018
    Publication date: June 17, 2021
    Applicant: Intervet Inc.
    Inventor: Ian Tarpey
  • Patent number: 10927172
    Abstract: The present invention provides caninized murine anti-human PD-1 antibodies that have specific sequences and a high binding affinity for canine PD-1. The invention also relates to use of these antibodies in the treatment of dogs.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: February 23, 2021
    Assignee: INTERVET INC.
    Inventors: Mohamad Morsey, Yuanzheng Zhang, Denise Bartels-Morozov, Jason Erskine, Ian Tarpey, Leonard Presta
  • Publication number: 20200354450
    Abstract: The present invention discloses antibodies to canine PD-1 that have specific sequences and a high binding affinity for canine PD-1. The invention also discloses the use of the antibodies of the present invention in the treatment of cancer in dogs.
    Type: Application
    Filed: June 5, 2020
    Publication date: November 12, 2020
    Applicant: Intervet Inc.
    Inventors: Mohamad Morsey, Yuanzheng Zhang, Denise Bartels-Morozov, Jason Erskine, Ian Tarpey
  • Publication number: 20200345832
    Abstract: The present invention provides a vaccine for rabies virus and methods of making and using the vaccine alone, or in combinations with other protective agents.
    Type: Application
    Filed: November 5, 2018
    Publication date: November 5, 2020
    Applicant: Intervet Inc.
    Inventor: Ian Tarpey
  • Publication number: 20200338186
    Abstract: The present invention provides new feline calicivirus vaccines, including multivalent vaccines. The present invention also provides methods of making and using the vaccines.
    Type: Application
    Filed: November 5, 2018
    Publication date: October 29, 2020
    Applicant: Intervet Inc.
    Inventor: Ian Tarpey
  • Publication number: 20200323978
    Abstract: The present invention discloses novel recombinant multivalent non-pathogenic Marek's Disease virus constructs that encode and express foreign antigens from three or more avian viruses, along with methods of the use of the multivalent poultry virus vaccines.
    Type: Application
    Filed: October 11, 2018
    Publication date: October 15, 2020
    Applicant: Intervet Inc.
    Inventors: Stephanie M. COOK, Mohamad MORSEY, Ian TARPEY
  • Publication number: 20200254088
    Abstract: The present invention provides new multivalent vaccines for felines. The present invention also provides methods of making and using the multivalent vaccines alone or in combinations with other protective agents.
    Type: Application
    Filed: November 5, 2018
    Publication date: August 13, 2020
    Applicant: Intervet Inc.
    Inventors: Zhichang Xu, Rhonda LaFleur, Ian Tarpey
  • Patent number: 10711061
    Abstract: The present invention discloses antibodies to canine PD-1 that have specific sequences and a high binding affinity for canine PD-1. The invention also discloses the use of the antibodies of the present invention in the treatment of cancer in dogs.
    Type: Grant
    Filed: February 12, 2018
    Date of Patent: July 14, 2020
    Assignee: Intervet Inc.
    Inventors: Mohamad Morsey, Yuanzheng Zhang, Denise Bartels-Morozov, Jason Erskine, Ian Tarpey
  • Publication number: 20200109212
    Abstract: The present disclosure describes antibodies including caninized antibodies against canine PD-L1 with specific properties. The document relates to epitopes of canine PD-L that bind to these antibodies, as well as to anti-canine PD-L1 antibodies that bind these epitopes, and to the use of the caninized anti-canine PD-L1 antibodies in the treatment of cancer in dogs.
    Type: Application
    Filed: December 18, 2019
    Publication date: April 9, 2020
    Applicant: Intervet Inc.
    Inventors: Mohamad Morsey, Yuanzheng Zhang, Denise Bartels-Morozov, Jason Erskine, Ian Tarpey
  • Patent number: 10550194
    Abstract: The present disclosure describes antibodies including caninized antibodies against canine PD-L1 with specific properties. The document relates to epitopes of canine PD-L1 that bind to these antibodies, as well as to anti-canine PD-L1 antibodies that bind these epitopes, and to the use of the caninized anti-canine PD-L1 antibodies in the treatment of cancer in dogs.
    Type: Grant
    Filed: September 29, 2015
    Date of Patent: February 4, 2020
    Assignee: Intervet Inc.
    Inventors: Mohamad Morsey, Yuanzheng Zhang, Denise Bartels-Morozov, Jason Erskine, Ian Tarpey
  • Publication number: 20190008950
    Abstract: The present invention is drawn to liquid stable poultry vaccines that comprise a live avian virus. The invention is also drawn to the manufacture of such vaccines and methods of vaccinating animal subjects with these vaccines.
    Type: Application
    Filed: September 14, 2018
    Publication date: January 10, 2019
    Applicant: Intervet Inc.
    Inventors: Zhisong Qiao, Stephanie Cook, Kevin O'Connell, Ian Tarpey
  • Publication number: 20190002562
    Abstract: The present invention discloses caninized antibodies with specific properties. The present invention also discloses caninized murine antibodies against canine PD-1 that have a high binding affinity for canine PD-1. The invention further discloses the use of the caninized antibodies of the present invention in the treatment of cancer in dogs.
    Type: Application
    Filed: September 13, 2018
    Publication date: January 3, 2019
    Applicant: Intervet Inc.
    Inventors: Mohamad Morsey, Yuanzheng Zhang, Ian Tarpey
  • Publication number: 20180346570
    Abstract: The present invention provides caninized murine anti-human PD-1 antibodies that have specific sequences and a high binding affinity for canine PD-1. The invention also relates to use of these antibodies in the treatment of dogs.
    Type: Application
    Filed: June 13, 2018
    Publication date: December 6, 2018
    Applicant: Intervet Inc.
    Inventors: Mohamad Morsey, Yuanzheng Zhang, Denise Bartels-Morozov, Jason Erskine, Ian Tarpey, Leonard Presta
  • Patent number: 10106607
    Abstract: The present invention discloses caninized antibodies with specific properties. The present invention also discloses caninized murine antibodies againstcanine PD-1 that have a high binding affinity for canine PD-1. The invention further discloses the use of the caninized antibodies of the present invention in the treatment of cancer in dogs.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: October 23, 2018
    Assignee: Intervet Inc.
    Inventors: Mohamad Morsey, Yuanzheng Zhang, Ian Tarpey
  • Publication number: 20180251554
    Abstract: The present invention discloses antibodies to canine PD-1 that have specific sequences and a high binding affinity for canine PD-1. The invention also discloses the use of the antibodies of the present invention in the treatment of cancer in dogs.
    Type: Application
    Filed: February 12, 2018
    Publication date: September 6, 2018
    Applicant: Intervet Inc.
    Inventors: Mohamad Morsey, Yuanzheng Zhang, Denise Bartels-Morozov, Jason Erskine, Ian Tarpey
  • Publication number: 20180237535
    Abstract: The present disclosure describes antibodies including caninized antibodies against canine PD-L1 with specific properties. The document relates to epitopes of canine PD-L1 that bind to these antibodies, as well as to anti-canine PD-L1 antibodies that bind these epitopes, and to the use of the caninized anti-canine PD-L1 antibodies in the treatment of cancer in dogs.
    Type: Application
    Filed: September 29, 2015
    Publication date: August 23, 2018
    Applicant: Intervet Inc.
    Inventors: Mohamad Morsey, Yuanzheng Zhang, Denise Bartels-Morozov, Jason Erskine, Ian Tarpey
  • Patent number: 10023636
    Abstract: The present invention provides caninized murine anti-human PD-1 antibodies that have specific sequences and a high binding affinity for canine PD-1. The invention also relates to use of these antibodies in the treatment of dogs.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: July 17, 2018
    Assignee: Intervet Inc.
    Inventors: Mohamad Morsey, Yuanzheng Zhang, Denise Bartels-Morozov, Jason Erskine, Ian Tarpey, Leonard G. Presta
  • Publication number: 20180104328
    Abstract: The present invention is drawn to liquid stable poultry vaccines that comprise a live avian virus. The invention is also drawn to the manufacture of such vaccines and methods of vaccinating animal subjects with these vaccines.
    Type: Application
    Filed: October 20, 2017
    Publication date: April 19, 2018
    Applicant: Intervet Inc.
    Inventors: Zhisong Qiao, Stephanie Cook, Kevin O'Connell, Ian Tarpey
  • Patent number: 9944704
    Abstract: The present invention discloses antibodies to canine PD-1 that have specific sequences and a high binding affinity for canine PD-1. The invention also discloses the use of the antibodies of the present invention in the treatment of cancer in dogs.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: April 17, 2018
    Assignee: Intervet Inc.
    Inventors: Mohamad Morsey, Yuanzheng Zhang, Denise Bartels-Morozov, Jason Erskine, Ian Tarpey
  • Patent number: 9827305
    Abstract: The present invention is drawn to liquid stable poultry vaccines that comprise avian virus. The invention is also drawn to the manufacture of such vaccines methods of vaccinating animal subjects with these vaccines.
    Type: Grant
    Filed: February 16, 2015
    Date of Patent: November 28, 2017
    Assignee: Intervet Inc.
    Inventors: Zhisong Qiao, Stephanie Cook, Kevin O'Connell, Ian Tarpey